Real-World Drug Survival of Ixekizumab for Psoriasis

Journal of the American Academy of Dermatology - United States
doi 10.1016/j.jaad.2019.01.034
Full Text
Abstract

Available in full text

Categories
Dermatology
Date
Authors
Publisher

Elsevier BV

Related search

Drug Survival of Secukinumab in Real-World Plaque Psoriasis Patients: A 52-Week, Multicenter, Retrospective Study

Journal of the American Academy of Dermatology
Dermatology
2018English

Toxoplasmosis in a Patient Receiving Ixekizumab for Psoriasis

JAAD Case Reports
Dermatology
2020English

Emerging Targeted Therapies for Plaque Psoriasis &Ndash; Impact of Ixekizumab

Clinical, Cosmetic and Investigational Dermatology
Dermatology
2017English

Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ixekizumab: Targeting Plaque Psoriasis and Psoriatic Arthritis

Prescriber
Pharmacology
2019English

Psy29 - Real-World Discontinuation of Biological Treatments in Moderate-To-Severe Plaque Psoriasis Over the First 5 Years of Treatment – A Literature Review of Drug Survival

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Real‐World Evidence of Secukinumab in Psoriasis Treatment – A Meta‐Analysis of 43 Studies

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy